Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent.

Literature DB >> 27069340

Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent.

Abstract

Paliperidone palmitate three-month injection (Invega Trinza): the first four-times-a-year, long-acting injectable antipsychotic agent for schizophrenia.

Entities: Chemical Disease

Year: 2016 PMID： 27069340 PMCID： PMC4811251

Source DB: PubMed Journal: P T ISSN： 1052-1372

14 in total

1. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.

Authors: Paulien Ravenstijn; Bart Remmerie; Adam Savitz; Mahesh N Samtani; Isaac Nuamah; Cheng-Tao Chang; Marc De Meulder; David Hough; Srihari Gopal
Journal: J Clin Pharmacol Date: 2015-10-05 Impact factor: 3.126

Review 2. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Authors: Evanthia Achilla; Paul McCrone
Journal: Appl Health Econ Health Policy Date: 2013-04 Impact factor: 2.561

3. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

Authors: D Robinson; M G Woerner; J M Alvir; R Bilder; R Goldman; S Geisler; A Koreen; B Sheitman; M Chakos; D Mayerhoff; J A Lieberman
Journal: Arch Gen Psychiatry Date: 1999-03

Review 4. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Authors: Natalie C Edwards; Jacqueline Pesa; Dennis M Meletiche; Luella Engelhart; Ann K Thompson; Jay Sherr; Riad Dirani
Journal: Curr Med Res Opin Date: 2008-12 Impact factor: 2.580

Review 5. Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.

Authors: Rimal B Bera
Journal: J Clin Psychiatry Date: 2014 Impact factor: 4.384

6. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Authors: José M Olivares; Alfonso Rodriguez-Martinez; José A Burón; David Alonso-Escolano; Alexander Rodriguez-Morales
Journal: Appl Health Econ Health Policy Date: 2008 Impact factor: 2.561

7. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.

Authors: Thomas R Einarson; Colin Vicente; Roman Zilbershtein; Charles Piwko; Christel N Bø; Hanna Pudas; Rasmus Jensen; Michiel E H Hemels
Journal: Nord J Psychiatry Date: 2013-11-25 Impact factor: 2.202

8. Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model.

Authors: Nicolas M Furiak; James C Gahn; Robert W Klein; Stephen B Camper; Kent H Summers
Journal: Ann Gen Psychiatry Date: 2012-11-16 Impact factor: 3.455

9. Perspectives on reasons of medication nonadherence in psychiatric patients.

Authors: Derya Güliz Mert; Nergiz Hacer Turgut; Meral Kelleci; Murat Semiz
Journal: Patient Prefer Adherence Date: 2015-01-13 Impact factor: 2.711

Review 10. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.

Authors: Gabriel Kaplan; Julio Casoy; Jacqueline Zummo
Journal: Patient Prefer Adherence Date: 2013-11-13 Impact factor: 2.711

5 in total

Review 1. Chemical Conjugation in Drug Delivery Systems.

Authors: Alexis Eras; Danna Castillo; Margarita Suárez; Nelson Santiago Vispo; Fernando Albericio; Hortensia Rodriguez
Journal: Front Chem Date: 2022-05-26 Impact factor: 5.545

2. Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.

Authors: Clifton Blackwood; Panna Sanga; Isaac Nuamah; Alexander Keenan; Arun Singh; Maju Mathews; Srihari Gopal
Journal: Patient Prefer Adherence Date: 2020-07-02 Impact factor: 2.711